AB
VTGN icon

Amalgamated Bank’s VistaGen Therapeutics VTGN Stock Holding History

Amalgamated Bank’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,052
Closed -$4K – 3129
2023
Q1 		$4K Buy
1,052
+55
+6% +$288 ﹤0.01% 2916
2022
Q4 		$3K Hold
997
– – ﹤0.01% 2958
2022
Q3 		$5K Buy
997
+13
+1% +$129 ﹤0.01% 2989
2022
Q2 		$26K Sell
984
-28
-3% -$989 ﹤0.01% 2791
2022
Q1 		$38K Sell
1,012
-80
-7% -$3.49K ﹤0.01% 2597
2021
Q4 		$64K Sell
1,092
-11
-1% -$716 ﹤0.01% 2099
2021
Q3 		$91K Sell
1,103
-51
-4% -$4.43K ﹤0.01% 2089
2021
Q2 		$109K Buy
+1,154
New +$85.5K ﹤0.01% 2112

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amalgamated Bank's VTGN Position: Q2 2023 in Review

Amalgamated Bank sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 1,052 shares — an estimated $4K sold.

Amalgamated Bank first reported a position in VTGN in Q2 2021 and held it in 8 quarters. The position peaked at $109K in Q2 2021. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

  • Amalgamated Bank reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Amalgamated Bank sold 1,052 VistaGen Therapeutics shares in Q2 2023, an estimated $4K.
  • Amalgamated Bank first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 8 quarters.
  • Amalgamated Bank's VistaGen Therapeutics position peaked at $109K in Q2 2021.
  • 33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on Amalgamated Bank's 13F filing for Q2 2023, filed 11 Aug 2023.